Innocoll AG (INNL) Lowered to “Hold” at Zacks Investment Research
Innocoll AG (NASDAQ:INNL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Innocoll Holdings develops and manufactures pharmaceutical products and medical devices through its proprietary collagen-based technologies. The company’s product include CollaGUARD(Ex-US), CollatampG(R), Septocoll(R), RegenePro(R), Collieva(R), CollaCare(R), Collexa(R) and Zorpreva(TM). It operates primarily in Asia, Australia, Canada, Europe, Latin America, the Middle East and the United States. Innocoll AG, formerly known as Innocoll GmbH, is headquartered in Athlone, Ireland. “
Other analysts also recently issued reports about the stock. JMP Securities reiterated a “buy” rating on shares of Innocoll AG in a report on Sunday, November 6th. FBR & Co cut their price target on shares of Innocoll AG from $18.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, November 4th.
Shares of Innocoll AG (NASDAQ:INNL) traded up 6.74% during trading on Wednesday, hitting $2.85. The firm has a 50 day moving average of $4.37 and a 200 day moving average of $5.98. Innocoll AG has a 12-month low of $2.20 and a 12-month high of $12.94. The stock’s market cap is $84.65 million.
Innocoll AG (NASDAQ:INNL) last released its earnings results on Tuesday, November 22nd. The specialty pharmaceutical company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.03. Innocoll AG had a negative return on equity of 1,226.28% and a negative net margin of 1,284.37%. On average, equities analysts forecast that Innocoll AG will post ($2.34) earnings per share for the current year.
About Innocoll AG
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innocoll AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll AG and related companies with MarketBeat.com's FREE daily email newsletter.